Blockchain Registration Transaction Record

Quantum BioPharma Advances MS Treatment with UK Regulatory Submission

Quantum BioPharma submits Lucid-MS to UK's ILAP program, aiming to accelerate access to a groundbreaking MS treatment. A leap forward in neurodegenerative therapy.

Quantum BioPharma Advances MS Treatment with UK Regulatory Submission

This news is pivotal for individuals affected by multiple sclerosis and the broader medical community. The submission of Lucid-MS to the ILAP program represents a beacon of hope for accelerating the availability of a potentially transformative treatment. Multiple sclerosis, a debilitating condition with limited treatment options, affects millions worldwide. Quantum BioPharma's innovative approach to targeting the disease's underlying mechanisms could significantly improve patients' quality of life. Furthermore, this development highlights the importance of regulatory pathways like ILAP in bridging the gap between groundbreaking research and patient access to new therapies.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0xaf5501b3f4d28bad1f277852ba73187ee443edaebe2a6e414addabf0db17b5b6
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintfilo_Up4-0b70ed68017ee5aa45ffc081b961cfe6